编码ERBB2胞内结构域的质粒DNA疫苗在晚期ERBB2阳性乳腺癌患者中的安全性与结局:1期非随机临床试验
该单臂1期试验纳入66例晚期ERBB2阳性乳腺癌患者,按10、100、500 μg三档剂量序贯接种编码ERBB2胞内结构域的质粒DNA疫苗,主要评估安全性与免疫原性。疫苗相关毒性多为1-2级且各剂量组间无显著差异;100 μg和500 μg组多数时间点的ERBB2 ICD 1型免疫反应幅度高于10 μg组。100 μg剂量在多数患者中可诱导ERBB2特异性1型T细胞,目前正在随机2期试验中评估。
要点
- 66例晚期ERBB2阳性乳腺癌患者序贯入组10、100、500 μg三档剂量,疫苗相关毒性多为1-2级。
- 校正基线因素后,100 μg组和500 μg组多数时间点ERBB2 ICD 1型免疫反应幅度高于10 μg组。
- 第16周疫苗部位DNA持续存在的患者,免疫接种结束后各时间点ERBB2 ICD免疫平均显著较低。
核心结论
- 在该1期非随机临床试验中,100 μg ERBB2 ICD质粒DNA疫苗免疫与多数ERBB2表达乳腺癌患者产生ERBB2特异性1型T细胞相关,目前正在随机2期试验中评估。
研究设计与样本
- 单臂1期试验,纳入66例晚期ERBB2阳性乳腺癌患者,2001年至2010年在一家学术医疗中心治疗,并进行了10年疫苗后毒性评估。
- 患者按序贯方式入组3个剂量组(10、100、500 μg),疫苗每月皮内接种1次、共3次免疫,以可溶性粒细胞-巨噬细胞集落刺激因子为佐剂。
- 安全性按不良事件通用术语标准3.0版分级,ERBB2 ICD免疫反应通过干扰素-γ酶联免疫斑点法测定。
- 数据分析于两个时段进行:2012年1月至2013年3月以及2021年7月至2022年8月。
主要发现
- 共66例患者入组,中位(范围)年龄51(34-77)岁。
- 多数疫苗相关毒性为1级和2级,各剂量组间无显著差异。
- 校正基线因素后,100 μg组(第2组)相比10 μg组(第1组)的ERBB2 ICD 1型免疫反应系数为181(95%CI 60-303),P=0.003;500 μg组(第3组)相比10 μg组系数为233(95%CI 102-363),P<0.001。
- 第16周疫苗部位DNA持续存在的患者,免疫接种结束后各时间点的ERBB2 ICD免疫平均显著低于无DNA持续存在者。
- 最高疫苗剂量与注射部位DNA持续存在的最高发生率相关。
关键数值与推荐
- 疫苗剂量为10、100、500 μg三个序贯剂量组。
- 免疫方案为每月皮内接种1次、共3次免疫,以可溶性粒细胞-巨噬细胞集落刺激因子为佐剂。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: High levels of ERBB2 (formerly HER2)-specific type 1 T cells in the peripheral blood are associated with favorable clinical outcomes after trastuzumab therapy; however, only a minority of patients develop measurable ERBB2 immunity after treatment. Vaccines designed to increase ERBB2-specific T-helper cells could induce ERBB2 immunity in a majority of patients. OBJECTIVE: To determine the safety and immunogenicity of 3 doses (10, 100, and 500 μg) of a plasmid-based vaccine encoding the ERBB2 intracellular domain (ICD). DESIGN, SETTING, AND PARTICIPANTS: Single-arm phase 1 trial including 66 patients with advanced-stage ERBB2-positive breast cancer treated in an academic medical center between 2001 and 2010 with 10-year postvaccine toxicity assessments. Data analysis was performed over 2 periods: January 2012 to March 2013 and July 2021 to August 2022. INTERVENTIONS: Patients were sequentially enrolled to the 3 dose arms. The vaccine was administered intradermally once a month with soluble granulocyte-macrophage colony-stimulating factor as an adjuvant for 3 immunizations. Toxicity evaluations occurred at set intervals and yearly. Peripheral blood mononuclear cells were collected for evaluation of immunity. Biopsy of vaccine sites at weeks 16 and 36 measured DNA persistence. MAIN OUTCOMES AND MEASURES: Safety was graded by Common Terminology Criteria for Adverse Events, version 3.0, and ERBB2 ICD immune responses were measured by interferon-γ enzyme-linked immunosorbent spot. Secondary objectives determined if vaccine dose was associated with immunity and evaluated persistence of plasmid DNA at the vaccine site. RESULTS: A total of 66 patients (median [range] age, 51 [34-77] years) were enrolled. The majority of vaccine-related toxic effects were grade 1 and 2 and not significantly different between dose arms. Patients in arm 2 (100 μg) and arm 3 (500 μg) had higher magnitude ERBB2 ICD type 1 immune responses at most time points than arm 1 (10 μg) (arm 2 compared with arm 1, coefficient, 181 [95% CI, 60-303]; P = .003; arm 3 compared with arm 1, coefficient, 233 [95% CI, 102-363]; P < .001) after adjusting for baseline factors. ERBB2 ICD immunity at time points after the end of immunizations was significantly lower on average in patients with DNA persistence at week 16 compared with those without persistence. The highest vaccine dose was associated with the greatest incidence of persistent DNA at the injection site. CONCLUSIONS AND RELEVANCE: In this phase 1 nonrandomized clinical trial, immunization with the 100-μg dose of the ERBB2 ICD plasmid-based vaccine was associated with generation of ERBB2-specific type 1 T cells in most patients with ERBB2-expressing breast cancer, and it is currently being evaluated in randomized phase 2 trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00436254.
引用
- Disis MLN, Guthrie KA, Liu Y, et al. Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2023. PMID: 36326756. doi:10.1001/jamaoncol.2022.5143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。